Hospital Universitario de Jaén. Allergology Department, Jaén, Spain 2
Hospital Santa Bárbara. Allergology Department, Puertollano, Spain 3
Hospital Costa de la Luz de Huelva. Allergology Department, Huelva, Spain 4
Hospital Universitario Infanta Cristina. Allergology Department, Badajoz, Spain 5
Hospital Nisa. Allergology Department, Seville, Spain 6
ROXALL España, R&D Department, Zamudio, Spain
Published online: 27 November 2019
Accepted: 25 November 2019
Received:29 August 2019
. To evaluate the tolerability and efficacy of Olea europaea subcutaneous immunotherapy (SCIT) on patients with rhinoconjunctivitis.
. In this open clinical trial patients were assigned to an abbreviated build-up scheme. The outcomes were: number, percentage, and severity of adverse reactions. Secondary outcomes included: changes in immunoglobulin titers and changes in dose-response skin prick tests. Results. Only 8 systemic reactions were registered, which represented 7/47 (14.9%) of patients and 8/429 (1.9%) of administered doses. Regarding immunological parameters the significant increases of sIgG and sIgG4 evidenced the changes in the patient immune system. Cutaneous reactivity decreased significantly.
. Olea europaea SCIT (Allergovac® depot ROXALL Medicina España S.A.) showed a good safety and tolerability profile. Immunological changes with induction of blocking IgG and decreases in cutaneous reactivity were detected in the patients.
Olea europaea; subcutaneous immunotherapy; rhinoconjunctivitis; abbreviated schedule; depot extracts